‘Now you stopped down ramping it, simply because you bought.’...

‘Now you stopped down ramping it, simply because you bought.’ ~@newB

Yes I see what you mean @newB, on reflection, I really have been really positively pumping the tires of Starpharma over the last week to get the share price up now that I’m a holder. Here’s some of my positive pumps and ramps since I joined the pom-pom club:

Yes @col69 but of course Eli Lilly were just one of many Starpharma partners that just magically and mysteriously faded from view without any ASX announcement to the best of my knowledge. Seriously, how can this be allowed to happen? If new Starpharma punters out there think that Starpharma is going to spoon feed you, think again.

The Starpharma share price has tanked 33% in less than 2 months since the new CEO was appointed. I know who’s being schooled here, and it ain’t me. Another record low here today at 12 cents, and possibly more records to tumble for all the reasons and risks I have outlined previously. Be careful out there.

And there we have it, it’s official. Starpharma dumped from All Ordinaries Index as expected. Starpharma is well and truly in microcap territory now and possibly at risk of more institutional selling if the fund’s rules do not allow holding stocks outside of the All Ords Index.

What an achievement by the board with ‘more than 100 years collective experience’ to paraphrase a boast by the Chairman. Will we see a commensurate reduction in the size of the board and/or a reduction in salary for directors and KMP? Not bloody likely. What a sad and sorry tale this company has become.

I honestly think there will be opportunities to pick up SPL sub 10 cents by the end of FY if there are no DEP deals by then (which I’m not expecting) or no positive AZ news (which I’m hoping for)

As a successful commercial opportunity, Viraleze is pretty much dead and buried. The failed post-market trial (for hose already with Covid) sealed its fate IMO. An unfortunate own-goal. So because of the failed trial to reduce viral load in patients with Covid, and until there is in-human clinical evidence to prove that it prevents Covid, how can this product ever become a success? It can’t IMO.

Starpharna would have spent around $10m getting this loss-making product to market, and in doing so have spent 10s of thousands of staff hours distracting the company from its primary reason for existing. And that is developing DEP drugs.

Then we have tax-loss selling season approaching as well as long-term holder’s capitulating. The pressure on the share price is firmly to the downside IMO. My advice would be to take caution out there, and have patience if anyone is looking to take a position or to accumulate.

The company is in terminal decline without a big positive development, and real soon!

The main thing is that Starpharma have failed to conduct a human trial to test Viraleze as a preventative.

Viraleze has been a monumental commercial distraction for Starpharma for over 3 years. This is a loss making product with IMO low prospects for commercial success going forward.

IMO Viraleze has resulted in Starpharma getting offside with multiple regulators, has damaged Starpharma’s reputation and has hijacked the company’s core oncology focus and used up significant and critical funds in doing so.

I can’t help but feel that if there’s no DEP deal imminent, and I see no reason to believe there will be, then we are inching towards capital raising territory in late Q2 or in Q3 of this CY.

We need some seriously positive news and developments involving cold hard cash, and soon. More research agreements and no-fee Viraleze territory licences will not move the dial.

I would estimate that Viraleze sales, worldwide in the last hour, added $40 to Starpharma’s bottom line. Yes, forty dollars. That’s 40 cents per country per hour.

Is there literally anyone, anyone else left to blame for the company being in the toilet at 13 cents?

We will never see the dollar amount but I would love to know how much money Starpharma have poured down the drain on consultants over the last 5 years.

‘Viraleze™ reduced viral load in the full study population including all patient age groups (N=197), although the difference vs placebo was not statistically significant’End of story.

Another month almost gone and still no new VivaGel distribution partner for Europe. More lost revenue opportunity = more cash leaking from the balance sheet.

What this does show is that Starpharma still have room for improvement with administrative housekeeping and attention to detail. Sloppy.